Market Place
Sourcing Support
Xeris Biopharma Reports Q3 2024 Financial Results
08 Nov 2024 //
BUSINESSWIRE
Xeris Announces Inducement Grants Under NASDAQ Rule
04 Oct 2024 //
BUSINESSWIRE
Xeris to Participate in Upcoming Investor Conferences
22 Aug 2024 //
BUSINESSWIRE
Xeris Biopharma Reports Second Quarter 2024 Financial Results
08 Aug 2024 //
BUSINESSWIRE
Xeris Biopharma To Report Q2 2024 Results On August 8
25 Jul 2024 //
BUSINESSWIRE
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 Jul 2024 //
BUSINESSWIRE
Xeris` Levoketoconazole Effects In Cushing`s Syndrome At ENDO
03 Jun 2024 //
BUSINESSWIRE
Xeris Positive Phase 2 Data Once-Weekly Levothyroxine XP-8121
30 May 2024 //
BUSINESSWIRE
Xeris to Participate in the Jefferies Global Healthcare Conference
30 May 2024 //
BUSINESSWIRE
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
09 May 2024 //
BUSINESSWIRE
Xeris collaborates with Beta Bionics for worldwide license agreement
06 May 2024 //
ACCESSWIRE
Xeris partners with Beta Bionics for exclusive collaboration.
06 May 2024 //
BUSINESSWIRE
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
02 May 2024 //
BUSINESSWIRE
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 Apr 2024 //
BUSINESSWIRE
Xeris to Participate in the 23rd Annual Needham Virtual Healthcare Conference
02 Apr 2024 //
BUSINESSWIRE
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
06 Mar 2024 //
BUSINESSWIRE
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Xeris to Present at Oppenheimer 34th Annual Healthcare Life Science Conference
05 Feb 2024 //
BUSINESSWIRE
Xeris Pharma Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Jan 2024 //
BUSINESSWIRE
Xeris Biopharma Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
27 Sep 2023 //
BUSINESSWIRE
Xeris Ships One Millionth Gvoke® Unit
31 Jul 2023 //
BUSINESSWIRE
Xeris Biopharma dosing patients in hypothyroidism drug trial
22 Jun 2023 //
CLINICAL TRIALS ARENA
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study
21 Jun 2023 //
BUSINESSWIRE
FDA Issues First Untitled Letter of the Year to Xeris Pharmaceuticals
17 Jun 2023 //
JDSPURA
OPDP hands first untitled letter in twelve months to Xeris
14 Jun 2023 //
RAPS
FDA ad watchdog sends reprimand of 2023 to Xeris over ‘misleading’ drug claims
13 Jun 2023 //
ENDPTS
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
18 Apr 2023 //
BUSINESSWIRE
Xeris taking subcutaneous challenger to AbbVie drug into phase 2
20 Dec 2022 //
FIERCEPHARMA
Xeris starts work on subcutaneous version of rare disease drug
28 Nov 2022 //
FIERCEPHARMA
Xeris and Horizon enter partnership to develop teprotumumab
24 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
Xeris Biopharma to Report 3 Q 2022 Financial Results on Nov9, 2022
02 Nov 2022 //
BUSINESSWIRE
Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
10 Aug 2022 //
BUSINESS WIRE
Xeris Biopharma to Report 2nd Quarter 2022 Financial Results on August 10, 2022
03 Aug 2022 //
BUSINESSWIRE
Tetris Pharma to Be Acquired by Arecor Therapeutics
01 Aug 2022 //
BUSINESSWIRE
Xeris Announces Full Results From the Logics Study of Recorlev
12 May 2022 //
BUSINESSWIRE
Xeris Biopharma says Gvoke Kit Is Now Available for Severe Hypoglycemia
16 Mar 2022 //
BUSINESSWIRE
Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital
10 Mar 2022 //
BUSINESSWIRE
Xeris Biopharma Reports Q4 and Full-year 2021 Financial Results
10 Mar 2022 //
BUSINESSWIRE
Xeris scores FDA approval for rare disease med Recorlev
31 Dec 2021 //
FIERCEPHARMA
Xeris Biopharma Reports Q3 2021 Financial Results and Other Highlights
10 Nov 2021 //
BUSINESSWIRE
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
05 Oct 2021 //
BUSINESSWIRE
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris
05 Oct 2021 //
GLOBENEWSWIRE
Strongbridge Announces Court Hearing Date ApproveProposed Acquisition by Xeris
23 Sep 2021 //
GLOBENEWSWIRE
Xeris Pharmaceuticals to Present at Oppenheimer Fall Healthcare Life Sciences
17 Sep 2021 //
BUSINESSWIRE
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
14 Sep 2021 //
BUSINESSWIRE
Strongbridge Announces Shareholder Approval of Proposed Acquisition by Xeris
08 Sep 2021 //
GLOBENEWSWIRE
Xeris Pharmaceuticals to Present at the H.C. Wainwright Investment Conference
07 Sep 2021 //
BUSINESSWIRE
Xeris Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
01 Sep 2021 //
BUSINESSWIRE
Xeris Pharmaceuticals Shares Rise 18% on FDA Approval for sNDA
23 Aug 2021 //
MARKETWATCH
Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application
23 Aug 2021 //
BUSINESSWIRE
Xeris Pharmaceuticals Strengthens Its Patent Estate
19 Aug 2021 //
BUSINESSWIRE
Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®
13 Aug 2021 //
BUSINESSWIRE
Xeris Receives FDA Approval for Trial of Hypothyroidism Therapeutic
12 Aug 2021 //
MARKETSCREENER
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
BUSINESSWIRE
Xeris Pharmaceuticals Announces Executive Changes
29 Jul 2021 //
BUSINESSWIRE
Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results
29 Jul 2021 //
BUSINESSWIRE
Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules
29 Jul 2021 //
BUSINESSWIRE
Xeris Enters Into an Exclusive License and Supply Agreement
19 Jul 2021 //
BUSINESSWIRE
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule
02 Jul 2021 //
BUSINESSWIRE
